Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
ImproveR International (BI-001-IM)
- Conditions
- Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Nycomed
- Target Recruit Count
- 4000
- Registration Number
- NCT00290849
- Locations
- 🇩🇰
Nycomed, Roskilde, Denmark
Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)
- Conditions
- Coronary DiseaseAngina Pectoris
- Interventions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2010-03-15
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 4570
- Registration Number
- NCT00262054
- Locations
- 🇩🇪
First Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
🇩🇪Herz-Zentrum, Bad Krozingen, Germany
🇩🇪Segeberger Kliniken, Bad Segeberg, Germany
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
- Conditions
- Unstable AnginaMyocardial InfarctionAcute Disease
- First Posted Date
- 2004-10-07
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 13800
- Registration Number
- NCT00093158
- Locations
- 🇺🇸
Cardiovascular Research Foundation, New York, New York, United States
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
- Conditions
- Myocardial Infarction
- First Posted Date
- 2004-10-07
- Last Posted Date
- 2006-02-09
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 300
- Registration Number
- NCT00093184
- Locations
- 🇺🇸
The Heart Care Research Foundation, Blue Island, Illinois, United States
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
- Conditions
- Cardiovascular DiseaseCoronary Artery Bypass Surgery
- Interventions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT00079586
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
- Conditions
- Cardiovascular DiseaseCoronary Artery Bypass Surgery
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 125
- Registration Number
- NCT00079508
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
- Conditions
- Cardiac SurgeryCoronary Artery Bypass Surgery
- Interventions
- First Posted Date
- 2003-11-27
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT00073593
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
- Conditions
- ThrombocytopeniaCardiac DiseaseThrombosisCoronary Artery Bypass Surgery
- First Posted Date
- 2003-11-27
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 88
- Registration Number
- NCT00073580
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
- Conditions
- Heparin-Induced ThrombocytopeniaThrombosis
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 50
- Registration Number
- NCT00043940
- Locations
- 🇺🇸
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, United States
Study Of Angiomax In Infants Under Six Months With Thrombosis
- Conditions
- Thrombosis
- First Posted Date
- 2002-08-08
- Last Posted Date
- 2006-02-01
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 25
- Registration Number
- NCT00043277
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.